Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

 
• By Vibha Sharma
  
Larotrectinib
Vitrakvi Is First Tumor-Agnostic Treatment Recommended For Pan-EU Approval • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography